Swedish National Guidelines on Urothelial Carcinoma : 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma
(2022) In Scandinavian Journal of Urology 56(2). p.137-146- Abstract
Objective: To overview the updated Swedish National Guidelines on Urothelial Carcinoma 2021, with emphasis on non-muscle-invasive bladder cancer (NMIBC) and upper tract urothelial carcinoma (UTUC). Methods: A narrative review of the updated version of the Swedish National Guidelines on Urothelial Carcinoma 2021 and highlighting new treatment recommendations, with comparison to the European Association of Urology (EAU) guidelines and current literature. Results: For NMIBC the new EAU 2021 risk group stratification has been introduced for non-muscle invasive bladder cancer to predict risk of progression and the web-based application has been translated to Swedish (https://nmibc.net.). For patients with non-BCG -responsive disease... (More)
Objective: To overview the updated Swedish National Guidelines on Urothelial Carcinoma 2021, with emphasis on non-muscle-invasive bladder cancer (NMIBC) and upper tract urothelial carcinoma (UTUC). Methods: A narrative review of the updated version of the Swedish National Guidelines on Urothelial Carcinoma 2021 and highlighting new treatment recommendations, with comparison to the European Association of Urology (EAU) guidelines and current literature. Results: For NMIBC the new EAU 2021 risk group stratification has been introduced for non-muscle invasive bladder cancer to predict risk of progression and the web-based application has been translated to Swedish (https://nmibc.net.). For patients with non-BCG -responsive disease treatment recommendations have been pinpointed, to guide patient counselling in this clinical situation. A new recommendation in the current version of the guidelines is the introduction of four courses of adjuvant platinum-based chemotherapy to patients with advanced disease in the nephroureterectomy specimen (pT2 or higher and/or N+). Patients with papillary urothelial neoplasms with low malignant potential (PUNLMP) can be discharged from follow-up already after 3 years based on a very low subsequent risk of further recurrences. Conclusions: The current version of the Swedish national guidelines introduces a new risk-stratification model and follow-up recommendation for NMIBC and adjuvant chemotherapy after radical surgery for UTUC.
(Less)
- author
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- non-muscle invasive bladder cancer, Swedish national guidelines, upper tract urothelial carcinoma, Urothelial carcinoma
- in
- Scandinavian Journal of Urology
- volume
- 56
- issue
- 2
- pages
- 137 - 146
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:85125912554
- pmid:35225148
- ISSN
- 2168-1805
- DOI
- 10.1080/21681805.2022.2041086
- language
- English
- LU publication?
- yes
- id
- 524abf70-181e-4a2e-86c7-4ce0e0e1c80a
- date added to LUP
- 2022-04-21 14:12:42
- date last changed
- 2024-12-18 21:53:57
@article{524abf70-181e-4a2e-86c7-4ce0e0e1c80a, abstract = {{<p>Objective: To overview the updated Swedish National Guidelines on Urothelial Carcinoma 2021, with emphasis on non-muscle-invasive bladder cancer (NMIBC) and upper tract urothelial carcinoma (UTUC). Methods: A narrative review of the updated version of the Swedish National Guidelines on Urothelial Carcinoma 2021 and highlighting new treatment recommendations, with comparison to the European Association of Urology (EAU) guidelines and current literature. Results: For NMIBC the new EAU 2021 risk group stratification has been introduced for non-muscle invasive bladder cancer to predict risk of progression and the web-based application has been translated to Swedish (https://nmibc.net.). For patients with non-BCG -responsive disease treatment recommendations have been pinpointed, to guide patient counselling in this clinical situation. A new recommendation in the current version of the guidelines is the introduction of four courses of adjuvant platinum-based chemotherapy to patients with advanced disease in the nephroureterectomy specimen (pT2 or higher and/or N+). Patients with papillary urothelial neoplasms with low malignant potential (PUNLMP) can be discharged from follow-up already after 3 years based on a very low subsequent risk of further recurrences. Conclusions: The current version of the Swedish national guidelines introduces a new risk-stratification model and follow-up recommendation for NMIBC and adjuvant chemotherapy after radical surgery for UTUC.</p>}}, author = {{Liedberg, Fredrik and Kjellström, Sofia and Lind, Anna-Karin and Sherif, Amir and Söderkvist, Karin and Falkman, Karin and Thulin, Helena and Aljabery, Firas and Papantonio, Dimitrious and Ströck, Viveka and Öfverholm, Elisabeth and Jerlström, Tomas and Sandzen, Johan and Verbiene, Ingrida and Ullén, Anders}}, issn = {{2168-1805}}, keywords = {{non-muscle invasive bladder cancer; Swedish national guidelines; upper tract urothelial carcinoma; Urothelial carcinoma}}, language = {{eng}}, number = {{2}}, pages = {{137--146}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Journal of Urology}}, title = {{Swedish National Guidelines on Urothelial Carcinoma : 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma}}, url = {{http://dx.doi.org/10.1080/21681805.2022.2041086}}, doi = {{10.1080/21681805.2022.2041086}}, volume = {{56}}, year = {{2022}}, }